Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4287-4292

  Tan, Sing Huang ^a   Ida, Hiroshi ^b   Goh, Boon Cher ^a   Hsieh, Wenson ^c   Loh, Marie ^d   Ito, Yoshiaki ^b  

^a National University Hospital   (United Kingdom)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c Johns Hopkins Singapore   (Singapore)

^d BIOINFORMATICS INSTITUTE   (Singapore)

Author keywords

Hypermethylation; Nasopharyngeal cancer; RUNX3

Indexed keywords

PROTEIN MLH1; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR RUNX3; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA EXTRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA PRIMERS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS);

EID: 33846013934     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chan AT, Teo PM and Huang DP: Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 31: 794-801, 2004.
2. Seow A, Koh WP, Chia KS, Shi LM, Lee HP and Shanmugaratnam K: Trends in cancer incidence in Singapore 1968-2002. Singapore Cancer Registry Report No 6, 2004.
3. Goelz SE, Vogelstein B, Hamilton SR and Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187-190, 1985.
4. Cravo M, Pinto R, Fidalgo P, Chaves P, Gloria L, Nobre-Leitao C and Costa Mira F: Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 39: 434-438, 1996.
5. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
6. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
7. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138, 2000.
8. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC and Huang DP: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725, 1996.
9. Chow LS, Lo KW, Kwong J, To KF, Tsang KF, Lam CW, Dammann R and Huang DP: RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 109: 839-847, 2004.
10. Tsao SW, Liu Y, Wang X, Yuen PW, Leung SY, Yuen ST, Pan J, Nicholls JM, Cheung AL and Wong YC: The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer 39: 524-531, 2003.
11. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ and Huang DP: Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8: 131-137, 2002.
12. Wong TS, Tang KC, Kwong DL, Shan JS, Wei WI, Kwong WL and Yuen AP: Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol 22: 869-874, 2003.
13. Shanmugaratnam K: Histological typing of nasopharyngeal carcinoma. IARC Sci Publ: 3-12, 1978.
14. Ho JH: Stage classification of nasopharyngeal carcinoma: a review. IARC Sci Publ: 99-113, 1978.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
16. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER and Latif F: Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22: 147-150, 2003.
17. Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, Kanai Y, Hirohashi S, Kakizoe T, Habuchi T and Kato T: Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 169: 1541-1545, 2003.
18. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
19. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
20. Okuda T, van Deursen J, Hiebert SW, Grosveld G and Downing JR: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330, 1996.
21. Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P and Karsenty G: Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 16: 307-310, 1997.
22. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002.
23. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K and Ito Y: Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 274: 31577-31582, 1999.
24. Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T and Mori M: Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15: 129-135, 2006.
25. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y and Motoyama T: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94: 589-592, 2003.
26. Wada M, Yazumi S. Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y and Chiba T: Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 23: 2401-2407, 2004.
27. Mori T, Nomoto S., Koshikawa, K., Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A: Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 25: 380-388, 2005.
28. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ and Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med 37: 276-281, 2005.
29. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y and Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520, 2006.
30. Imamura Y, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K and Nakao A: RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res 25: 2627-2630, 2005.
31. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005.
32. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC and Ito Y: RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene, 2006 [Epub ahead of print].
33. Liggett WH Jr. and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
34. Zheng J, Li W and Huang R: Studies on c-myc gene expression and p16 gene inactivation in nasopharyngeal carcinoma. Zhonghua Er Bi Yan Hou Ke Za Zhi 35: 464-468, 2000.
35. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
36. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
37. Kim ST, Lim DS, Canman CE and Kastan MB: Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274: 37538-37543, 1999.
38. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ and Huang DP: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881, 2001.
39. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
40. Mareel M, Boterberg T, Noe V, Van Hoorde L, Vermeulen S, Bruyneel E and Bracke M: E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 173: 271-274, 1997.
41. Zheng Z, Pan J, Chu B, Wong YC, Cheung AL and Tsao SW: Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 30: 458-466, 1999.
42. Kao RH, Huang LC and Hsu YH: Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma. Anticancer Res 22: 4109-4113, 2002.
43. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ and Thibodeau SN: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58: 3455-3460, 1998.
44. Esteller M, Levine R, Baylin SB, Ellenson LH and Herman JG: MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17: 2413-2417, 1998.
45. Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K and Yasui W: DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 94: 901-905, 2003.